Related Experiment Video

Updated: May 13, 2025

Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier
07:53

Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier

Published on: April 26, 2016

11.0K

The potential of dibenzazepine carboxamides in cancer therapy

Nastaran Afsordeh1, Safura Pournajaf1, Javad Mirnajafi-Zadeh1

  • 1Department of Medical Physiology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.

Frontiers in Pharmacology
|April 14, 2025
PubMed

Insights

Dibenzazepine carboxamides, repurposed anticonvulsants, show promising anticancer effects by targeting key cellular pathways. Further research is needed to explore their full therapeutic potential in oncology.

Area of Science:

  • Oncology
  • Pharmacology
  • Drug Discovery

Background:

  • Cancer remains a leading global cause of mortality, with conventional treatments facing challenges like drug resistance.
  • Developing novel anticancer drugs is costly and time-consuming, making drug repurposing a strategic alternative.
  • Dibenzazepine carboxamides, known anticonvulsants, are emerging as potential anticancer agents.

Purpose of the Study:

  • To review the pharmacodynamics, pharmacokinetics, and clinical applications of dibenzazepines in oncology.
  • To explore the anticancer mechanisms of dibenzazepine carboxamides.
  • To highlight the therapeutic potential of these compounds in cancer treatment.

Main Methods:

  • Comprehensive literature review of dibenzazepine carboxamides.
  • Analysis of *in vitro* and *in vivo* studies demonstrating anticancer properties.
  • Examination of proposed anticancer mechanisms of action.

Main Results:

  • Dibenzazepine carboxamides exhibit anticancer properties through various mechanisms.
  • These mechanisms include induction of apoptosis, inhibition of histone deacetylase (HDAC), and modulation of Wnt/β-Catenin signaling.
  • Voltage-gated sodium channels are also implicated in their anticancer effects.

Conclusions:

  • Dibenzazepine carboxamides represent a promising class of compounds for cancer treatment.
  • Drug repurposing of these anticonvulsants offers a viable strategy to accelerate cancer drug development.
  • Further investigation is warranted to fully understand and optimize their application in oncology.
Keywords:
cancer therapycarbamazepinedibenzazepineseslicarbazepineoxcarbazepine

More Related Videos

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen19:44

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen

Published on: May 30, 2012

18.6K
Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents07:20

Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents

Published on: May 28, 2014

13.9K

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
185
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids01:21

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
190
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
152
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
140